Towa Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Towa Pharmaceutical's earnings have been declining at an average annual rate of -8.2%, while the Pharmaceuticals industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 16.6% per year. Towa Pharmaceutical's return on equity is 10.4%, and it has net margins of 7.2%.
Key information
-8.2%
Earnings growth rate
-8.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 16.6% |
| Return on equity | 10.4% |
| Net Margin | 7.2% |
| Next Earnings Update | 12 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Towa Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 235,952 | 16,918 | 65,493 | 0 |
| 31 Mar 24 | 227,934 | 16,173 | 50,493 | 13,242 |
| 31 Dec 23 | 236,779 | 11,735 | 53,438 | 15,265 |
| 30 Sep 23 | 225,755 | 6,462 | 53,217 | 15,265 |
| 30 Jun 23 | 218,035 | 5,556 | 53,120 | 15,265 |
| 31 Mar 23 | 208,859 | 2,201 | 51,934 | 15,265 |
| 31 Dec 22 | 180,407 | 2,898 | 49,087 | 11,488 |
| 30 Sep 22 | 173,861 | 9,364 | 45,048 | 11,488 |
| 30 Jun 22 | 168,060 | 11,998 | 42,720 | 11,488 |
| 31 Mar 22 | 165,615 | 15,914 | 40,160 | 11,488 |
| 31 Dec 21 | 165,262 | 19,511 | 38,353 | 10,642 |
| 30 Sep 21 | 162,514 | 16,949 | 37,403 | 10,642 |
| 30 Jun 21 | 159,927 | 15,934 | 35,722 | 10,642 |
| 31 Mar 21 | 154,900 | 13,958 | 34,881 | 10,642 |
| 31 Dec 20 | 141,230 | 12,981 | 34,253 | 8,566 |
| 30 Sep 20 | 129,674 | 13,688 | 31,546 | 8,566 |
| 30 Jun 20 | 119,878 | 14,074 | 29,137 | 8,566 |
| 31 Mar 20 | 110,384 | 14,503 | 25,909 | 8,566 |
| 31 Dec 19 | 111,218 | 13,989 | 25,475 | 7,916 |
| 30 Sep 19 | 111,315 | 14,364 | 25,296 | 7,916 |
| 30 Jun 19 | 108,016 | 13,673 | 24,198 | 7,916 |
| 31 Mar 19 | 105,104 | 13,475 | 24,200 | 7,916 |
| 31 Dec 18 | 101,309 | 9,577 | 23,732 | 7,725 |
| 30 Sep 18 | 97,871 | 8,369 | 23,652 | 7,725 |
| 30 Jun 18 | 96,411 | 8,056 | 24,194 | 7,725 |
| 31 Mar 18 | 93,430 | 6,495 | 23,682 | 7,725 |
| 31 Dec 17 | 91,660 | 8,145 | 22,472 | 9,352 |
| 30 Sep 17 | 89,126 | 9,794 | 22,301 | 9,352 |
| 30 Jun 17 | 87,285 | 8,680 | 22,481 | 9,352 |
| 31 Mar 17 | 84,949 | 5,576 | 22,552 | 9,352 |
| 31 Dec 16 | 84,582 | 6,180 | 23,411 | 8,924 |
| 30 Sep 16 | 83,474 | 3,755 | 23,500 | 8,924 |
| 30 Jun 16 | 82,862 | 4,345 | 22,657 | 8,924 |
| 31 Mar 16 | 82,115 | 7,684 | 21,795 | 8,924 |
| 31 Dec 15 | 79,649 | 8,521 | 23,259 | 6,144 |
| 30 Sep 15 | 77,164 | 11,064 | 22,008 | 6,144 |
| 30 Jun 15 | 74,414 | 12,076 | 20,464 | 6,144 |
| 31 Mar 15 | 71,470 | 11,118 | 19,723 | 6,144 |
| 31 Dec 14 | 69,181 | 9,758 | 19,258 | 5,296 |
| 30 Sep 14 | 66,260 | 8,041 | 18,373 | 5,296 |
| 30 Jun 14 | 63,232 | 6,075 | 18,126 | 5,296 |
| 31 Mar 14 | 61,351 | 5,992 | 17,144 | 5,296 |
| 31 Dec 13 | 58,762 | 6,342 | 17,163 | 4,478 |
Quality Earnings: 4553 has high quality earnings.
Growing Profit Margin: 4553's current net profit margins (7.2%) are higher than last year (2.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4553's earnings have declined by 8.2% per year over the past 5 years.
Accelerating Growth: 4553's earnings growth over the past year (204.5%) exceeds its 5-year average (-8.2% per year).
Earnings vs Industry: 4553 earnings growth over the past year (204.5%) exceeded the Pharmaceuticals industry 13%.
Return on Equity
High ROE: 4553's Return on Equity (10.4%) is considered low.